Roy F. Waldron
Direktor/Vorstandsmitglied bei Starton Therapeutics, Inc.
Aktive Positionen von Roy F. Waldron
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Starton Therapeutics, Inc.
 Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Direktor/Vorstandsmitglied | 01.05.2019 | - |
Karriereverlauf von Roy F. Waldron
Ehemalige bekannte Positionen von Roy F. Waldron
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Roy F. Waldron
| New York University School of Law | Graduate Degree |
| Yale University | Doctorate Degree |
| Dartmouth College | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Starton Therapeutics, Inc.
Starton Therapeutics, Inc. BiotechnologyHealth Technology Starton Therapeutics, Inc. is a clinical-stage biotechnology platform company that focuses on transforming standard of care therapies with proprietary continuous delivery technology. The company is based in Paramus, NJ. The company's goal is to provide continuous treatment to people with cancer so they can live better and longer. Starton's proprietary transdermal technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. The company was founded in 2017 by Pedro Lichtinger, who has been the CEO since 2017. | Health Technology |
- Börse
- Insiders
- Roy F. Waldron
- Erfahrung